Research Topics
| Fadia T ShayaSummaryAffiliation: University of Maryland Country: USA Publications
| Collaborators
|
Detail Information
Publications
Decision support tools to optimize economic outcomes for type 2 diabetesFadia T Shaya
University of Maryland School of Pharmacy, 220 Arch St, 12th Floor, Room 01 204, Baltimore, MD, USA
Am J Manag Care 17:S377-83. 2011..It will also provide guidance on common indices of comorbidity used in health economics research. Data from these models can be used to reduce treatment costs and improve the overall quality of population-level health...
Comparison of physician practice patterns for older adults compared to NHANES diabetes cohort on oral/other therapyFadia T Shaya
University of Maryland School of Pharmacy, Baltimore, MD, USA
Expert Rev Pharmacoecon Outcomes Res 13:153-60. 2013..98; p = 0.07) per additional year of diabetes history. Results suggest that sicker, older patients might benefit from more aggressive therapy, in the context of diabetes prevalence, this is expected to continue rising in that population...
Social networks help control hypertensionFadia T Shaya
Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
J Clin Hypertens (Greenwich) 15:34-40. 2013..The clustering of patients in social networks around hypertension education has a positive impact on the management of hypertension in minority populations and may help address cardiovascular health disparities...- Diabetes knowledge in a high risk urban populationFadia T Shaya
Center on Drugs and Public Policy, University of Maryland School of Pharmacy, 515 West Lombard Street, 2nd Floor, Baltimore, MD 21201, USA
Ethn Dis 21:485-9. 2011..0104). The study indicated that patients who are exposed to the educational program end up with better knowledge on all counts, than patients who just go through the health care system in the course of usual care for diabetes... - The use of age-period-cohort analysis to determine the impact of economic development on COPD mortality in Hong KongFadia T Shaya
University of Maryland School of Pharmacy and School of Medicine, 220 Arch Street, Baltimore, MD 21201, USA
Expert Rev Pharmacoecon Outcomes Res 12:19-21. 2012.... - Health-related quality of life as a potential predictor in chronic obstructive lung disease patientsFadia T Shaya
Associate Professor and Associate Director, University of Maryland, Center on Drugs and Public Policy, School of Pharmacy, 220 Arch Street, Room 01 204, Baltimore, MD 21201, USA
Expert Rev Pharmacoecon Outcomes Res 7:129-35. 2007..Over a 3-month period, no change was seen in the patient-reported health-related quality of life and the change in health-related quality-of-life scores was not associated with disease severity... - The case for cultural competence in health professions educationFadia T Shaya
Center on Drugs and Public Policy, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
Am J Pharm Educ 70:124. 2006..Students should be grounded in cultural awareness and cultural sensitivity. This article establishes a case for integrating cultural competence into the curricula of health professions schools... - Bridging the gap between pharmacoeconomics and the real-world practice of managed care pharmacyFadia T Shaya
University of Maryland School of Pharmacy, 220 Arch St, 12th Fl, Baltimore, MD 21201, USA
J Manag Care Pharm 13:66-7. 2007 - A perspective on African American participation in clinical trialsFadia T Shaya
Center on Drugs and Public Policy, University of Maryland School of Pharmacy, Pharmaceutical Health Services Research, 220 Arch Street, Baltimore, MD 21201, USA
Contemp Clin Trials 28:213-7. 2007.... - Burden of COPD, asthma, and concomitant COPD and asthma among adults: racial disparities in a medicaid populationFadia T Shaya
Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
Chest 136:405-11. 2009.... - School-based obesity interventions: a literature reviewFadia T Shaya
Center on Drugs and Public Policy, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
J Sch Health 78:189-96. 2008..This article is an overview of different interventions conducted in school settings so as to guide efforts for an effective management of obesity in children, thus minimizing the risk of adult obesity and related cardiovascular risk... - Burden of concomitant asthma and COPD in a Medicaid populationFadia T Shaya
Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, 220 Arch St, Twelfth Floor, Baltimore, MD 21201, USA
Chest 134:14-9. 2008..This study compares utilization outcomes in patients with asthma, COPD, or co-occurring asthma and COPD in a Medicaid population, and assesses the incremental burden of COPD in patients with asthma... - Predictors of compliance with antihypertensive therapy in a high-risk medicaid populationFadia T Shaya
Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, 220 Arch St, 12th Floor, Baltimore, MD 21201, USA
J Natl Med Assoc 101:34-9. 2009..To identify predictors of compliance with antihypertensive combination therapy in a Medicaid population... - Elevated economic burden in obstructive lung disease patients with concomitant sleep apnea syndromeFadia T Shaya
Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD, 21201, USA
Sleep Breath 13:317-23. 2009..The purpose of this study is to examine the incremental economic burden of sleep apnea syndrome (SAS) among individuals with concomitant asthma, chronic obstructive pulmonary disease (COPD), or both (i.e., asthma/COPD)... - US trends in glycemic control, treatment, and comorbidity burden in patients with diabetesFadia T Shaya
University of Maryland, School of Pharmacy, Pharmaceutical Health Services Research, 220 Arch Street, Baltimore, MD 21201, USA
J Clin Hypertens (Greenwich) 12:826-32. 2010..The results indicate a high percentage of poor glycemic control among persons with diabetes. There were also a substantial number of comorbid conditions associated with diabetes... - Social networks in cardiovascular disease managementFadia T Shaya
University of Maryland School of Pharmacy, 220 Arch Street, 12th Floor Baltimore, MD 21201, USA
Expert Rev Pharmacoecon Outcomes Res 10:701-5. 2010..The patient-centered medical home can serve as an adaptive source for social network evolvement... - Drug therapy persistence and stroke recurrenceFadia T Shaya
Department of Epidemiology and Preventive Medicine, University of Maryland, 515 West Lombard St, Baltimore, MD 21201, USA
Am J Manag Care 12:313-9. 2006..To assess the effect of persistence of use of warfarin sodium, aspirin, or clopidogrel bisulfate on stroke recurrence in a Medicaid high-risk, largely female, African American population... - New treatment approaches to diabetesFadia T Shaya
University of Maryland School of Pharmacy, Center on Drugs and Public Policy, 515 W Lombard St #256, Baltimore, MD 21201, USA
Manag Care 15:38, 40-1. 2006 - Prescription drug spending trends for the privately insured in Maryland, 2000-2001Fadia T Shaya
Center on Drugs and Public Policy at the University of Maryland School of Pharmacy, USA
Health Aff (Millwood) 23:226-32. 2004..Findings suggest that a greater proportion of the economic burden of prescription drugs in coming years will be borne by those who use them... - Formulary decision-making considerations: COX-2 inhibitorsFadia T Shaya
Center on Drugs and Public Policy, University of Maryland School of Pharmacy, Baltimore 21201, USA
Manag Care Interface 17:29-36, 41. 2004..Particularly in light of recent events, the case of the cyclooxygenase-2 inhibitors for the treatment of arthritis yields interesting perspectives into formulary decision making... - Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid populationFadia T Shaya
Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
Arch Intern Med 165:181-6. 2005..This observational cohort study examines the cardiovascular risk of COX-2 inhibitors compared with nonspecific NSAIDs in Maryland Medicaid enrollees, a high-risk population... - Compliance with medicineFadia T Shaya
Department of Pharmaceutical Health Services Research, Center on Drugs and Public Policy, University of Maryland School of Pharmacy, 515 West Lombard Street, Room 256, Baltimore, MD 21201, USA
Ophthalmol Clin North Am 18:611-7. 2005..Such results may be best complemented by primary, survey-based data collected from patients in observational studies... - Prescriptions for cyclooxygenase-2 inhibitors and other nonsteroidal anti-inflammatory agents in a medicaid managed care population: African Americans versus CaucasiansFadia T Shaya
Center on Drugs and Public Policy, University of Maryland Baltimore School of Pharmacy, Baltimore, Maryland 21201, USA
Pain Med 6:11-7. 2005..To determine whether race is a predictor of a patient's likelihood of being prescribed selective cyclooxygenase-2 inhibitors (COX-2s) versus other nonsteroidal anti-inflammatory agents (NSAIDs) in Medicaid managed care plans (MCO)... - Medicaid managed care: disparities in the use of thiazolidinediones compared with metforminFadia T Shaya
Outcomes Research Epidemiology Center on Drugs and Public Policy University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
J Natl Med Assoc 97:493-7. 2005..To identify patient characteristics that are associated with the incidence of thiadolidinediones (TZDs) or metformin prescnbing in Medicaid managed care plans... - Assessing potential risks and evaluating expected benefitsFadia T Shaya
Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, School of Medicine, Epidemiology and Preventive Medicine, Baltimore 21201, USA
Manag Care Interface 18:27-30. 2005..It is unclear how this understanding of treatment benefit and harm should actually relate to a specific clinical decision... - Addressing cardiovascular disparities through community interventionsFadia T Shaya
Center on Drugs and Public Policy, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
Ethn Dis 16:138-44. 2006..To identify the components and impact of intervention programs aimed at reducing cardiovascular disparities... - Comparison of first refill rates among users of sertraline, paroxetine, and citalopramC Daniel Mullins
Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, USA
Clin Ther 28:297-305; discussion 296. 2006..Research suggests high rates of discontinuation of selective serotonin reuptake inhibitors (SSRIs)... - The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): a randomized trial of the effect of education on improving blood pressure control in a largely African American populationWallace Johnson
School of Medicine, University of Maryland, Baltimore, MD, USA
J Clin Hypertens (Greenwich) 13:563-70. 2011..Additional research should be conducted to evaluate whether the use of certified hypertension educators in collaboration with physicians will result in a similar blood pressure reduction... - Readmissions after unauthorized discharges in the cardiovascular settingEberechukwu Onukwugha
Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
Med Care 49:215-24. 2011.... - Health care cost of analgesic use in hypertensive patientsC Daniel Mullins
Center on Drugs and Public Policy, University of Maryland School of Pharmacy, Baltimore, Maryland, USA
Clin Ther 26:285-93. 2004..Hypertension is one of the most frequently diagnosed chronic medical conditions in the United States and imposes a substantial financial and social burden on Americans... - Ethnic disparities, hospital quality, and discharges against medical advice among patients with cardiovascular diseaseEbere Chukwu Onukwugha
Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
Ethn Dis 19:172-8. 2009..Disparities in discharges AMA have not been examined among patients with cardiovascular disease, nor has the moderating role of hospital quality been studied... - New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort studyJingshu Wang
Pharmaceutical Health Services Research Department, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
Ann Pharmacother 41:937-43. 2007..However, less is known about how the risk of hypertension is associated with cyclooxygenase 2 selective inhibitors (coxibs), especially celecoxib, the only coxib remaining on the market... - Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertensionTeisha A Robertson
School of Pharmacy, University of Maryland, Baltimore, MD, USA
Am J Manag Care 14:710-6. 2008..To determine the effect of medication burden on persistent use of newly added lipid-lowering (LL) drugs among patients with hypertension... - The burden of obstructive lung disease in Medicaid and managed care populationsFadia T Shaya
University of Maryland School of Pharmacy, Baltimore, MD, USA
Manag Care 14:20-3; discussion 24-6. 2005 - Predictors of fixed-dose combination antihypertensive drug therapy in a Medicaid populationFadia T Shaya
Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, Maryland, USA
J Am Soc Hypertens 2:469-75. 2008..Sickly male patients were more likely to receive the dual-agent component-based therapy. This information can assist future plans in medication therapy management... - Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopramC Daniel Mullins
Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, 21201, USA
Pharmacotherapy 25:660-7. 2005..To compare persistence, switching, and discontinuation rates among patients taking brand-name selective serotonin reuptake inhibitors (SSRIs)... - Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureusC Daniel Mullins
Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, USA
Clin Ther 28:1184-98. 2006..This study compared the cost-effectiveness of linezolid and vancomycin in the treatment of patients with nosocomial pneumonia (NP) caused by methicillin-resistant Staphylococcus aureus (MRSA)... - Persistence with overactive bladder pharmacotherapy in a Medicaid populationFadia T Shaya
Center on Drugs and Public Policy, University of Maryland School of Pharmacy, Baltimore, USA
Am J Manag Care 11:S121-9. 2005..47; 95% confidence interval, 1.01-2.14). CONCLUSION: Persistence rates are better for patients taking drugs with once-daily dosing, but there is a need for a better understanding of non-persistent patients... - The cost effectiveness and budget impact of natalizumab for formulary inclusionJustin Bakhshai
University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, USA
J Med Econ 13:63-9. 2010..The purpose of this study was to analyze the clinical and economic data associated with natalizumab (Tysabri) and to determine the potential impact of its formulary inclusion in a hypothetical health plan... - Disparities in prevalence rates for lung, colorectal, breast, and prostate cancers in MedicaidC Daniel Mullins
Center on Drugs and Public Policy, University of Maryland School of Pharmacy, 515 W Lombard St, Second Floor, Baltimore, MD 21201, USA
J Natl Med Assoc 96:809-16. 2004..Given previous reports of variations in prevalence of cancer in low-income individuals, we sought to determine if disparities in cancer prevalence existed in a similarly-insured Medicaid population... - Delivering cost-effective care for COPD in the USA: recent progress and current challengesIan M Breunig
Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, 220 Arch Street, 12th Floor, Room 01 209, Baltimore, MD 21201, USA
Expert Rev Pharmacoecon Outcomes Res 12:725-31. 2012..Only then can evidence-based guidelines be translated into the most cost-effective delivery of care... - A qualitative evaluation of a citywide Community Health Partnership programC Daniel Mullins
University of Maryland School of Pharmacy, Department of Pharmaceutical Health Services Research, Saratoga Building, 12th Floor, 220 Arch St, Baltimore, MD 21201, USA
J Natl Med Assoc 104:53-60. 2012..Through stakeholder engagement, many more communities beyond Baltimore can become better networked to help patients navigate the health care system and improve their health... - Clinical evaluation of natalizumab for formulary considerationAshley Bivins
University of Maryland School of Pharmacy, Center on Drugs and Public Policy, Baltimore, MD 21201, USA
Expert Opin Biol Ther 10:1279-87. 2010..Evaluation of natalizumab's clinical relevance must be performed before considering its place in treatment of these diseases... - Effect of initial ziprasidone dose on treatment persistence in schizophreniaC Daniel Mullins
University of Maryland School of Pharmacy, 515 W Lombard Street, Room 262, Baltimore, MD 21201, United States
Schizophr Res 83:277-84. 2006..To determine the relationship between ziprasidone initial dose and treatment persistence among patients diagnosed with schizophrenia... - Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whitesJunling Wang
Division of Health Science Administration, Department of Pharmaceutical Sciences, University of Tennessee College of Pharmacy, 847 Monroe Ave, Room 205R, Memphis, TN 38163, USA
Health Serv Res 42:1499-519. 2007..To examine racial and ethnic disparities in new prescription drug use... - Discontinuation rates of topical glaucoma medications in a managed care populationFadia T Shaya
Am J Manag Care 8:S271-7. 2002..CONCLUSION: In this managed care setting, rates of discontinuation in patients initially treated with latanoprost were lower than those of patients receiving comparator drugs... - Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whitesJunling Wang
University of Tennessee College of Pharmacy, USA
Med Care Res Rev 63:742-63. 2006..Disparities exist in new, essential drug acquisition between non-Hispanic whites and non-Hispanic blacks. Socioeconomic and health characteristics explain many of the observed disparities... - Summary quality scores for pharmacoeconomic studies: balancing validity with needFadia T Shaya
J Manag Care Pharm 9:87-8. 2003